<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32501768</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1949-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Gut microbes</Title><ISOAbbreviation>Gut Microbes</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis and intestinal microbiota-toward establishing cause and effect.</ArticleTitle><Pagination><StartPage>1833</StartPage><EndPage>1841</EndPage><MedlinePgn>1833-1841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/19490976.2020.1767464</ELocationID><Abstract><AbstractText>The intestinal microbiota may be involved, through metabolic gut-brain interactions, in a variety of neurological conditions. In this addendum, we summarize the findings of our recent study investigating the potentially modulatory influence of the microbiome in a transgenic ALS mouse model, and the possible application to human disease. We found that transgenic mice show evidence of dysbiosis, even at the pre-symptomatic stage, and have a more severe disease course under germ-free conditions or after receiving broad-spectrum antibiotics. We demonstrated that <i>Akkermansia muciniphila</i> ameliorated the disease in mice and that this may be due to the production of nicotinamide. We then conducted a preliminary study in human ALS and identified functionally similar alterations within the metagenome. Furthermore, we found that patients with ALS had lower systemic and CSF levels of nicotinamide, suggesting that the changes observed in the mouse model may be relevant to human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular/EMG Service and ALS/Motor Neuron Disease Clinic, Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center , Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kviatcovsky</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Immunology Department, Weizmann Institute of Science , Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elinav</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Immunology Department, Weizmann Institute of Science , Rehovot, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cancer-Microbiome Research, DKFZ , Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gut Microbes</MedlineTA><NlmUniqueID>101495343</NlmUniqueID><ISSNLinking>1949-0976</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N"> Akkermansia </Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">als</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">nicotinamide</Keyword><Keyword MajorTopicYN="N">sod1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32501768</ArticleId><ArticleId IdType="pmc">PMC7524331</ArticleId><ArticleId IdType="doi">10.1080/19490976.2020.1767464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013. March;12(3):310&#x2013;322. doi:10.1016/S1474-4422(13)70036-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70036-X</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson&#x2019;s disease. Cell. 2016. December;167(6):1469&#x2013;1480.e12. doi:10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, Zink EM, Casey CP, Taylor BC, Lane CJ, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019. May;177(6):1600&#x2013;1618.e17. doi:10.1016/j.cell.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.004</ArticleId><ArticleId IdType="pmc">PMC6993574</ArticleId><ArticleId IdType="pubmed">31150625</ArticleId></ArticleIdList></Reference><Reference><Citation>de Theije CGM, Wopereis H, Ramadan M, van Eijndthoven T, Lambert J, Knol J, Garssen J, Kraneveld AD, Oozeer R.. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun. 2014. March;37:197&#x2013;206. doi:10.1016/j.bbi.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.12.005</ArticleId><ArticleId IdType="pubmed">24333160</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013. October;8(10):e76993. doi:10.1371/journal.pone.0076993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076993</ArticleId><ArticleId IdType="pmc">PMC3793965</ArticleId><ArticleId IdType="pubmed">24130822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, Cionci NB, Gagg&#xec;a F, Lucenti A, Bersano E, et al. Potential role of gut microbiota in ALS pathogenesis and possible novel therapeutic strategies. J Clin Gastroenterol. 2018;52(Suppl 1):S68&#x2013;S70. Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition &amp; Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017. doi:10.1097/MCG.0000000000001042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001042</ArticleId><ArticleId IdType="pubmed">29782468</ArticleId></ArticleIdList></Reference><Reference><Citation>Erber AC, Cetin H, Berry D, Schernhammer ES. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci. 2019. December:1&#x2013;9. DOI:10.1080/00207454.2019.1702549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2019.1702549</ArticleId><ArticleId IdType="pubmed">31870202</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis M, Francavilla R, Piccolo M, De Giacomo A, Gobbetti M. Autism spectrum disorders and intestinal microbiota. Gut Microbes. 2015;6(3):207&#x2013;213. doi:10.1080/19490976.2015.1035855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2015.1035855</ArticleId><ArticleId IdType="pmc">PMC4616908</ArticleId><ArticleId IdType="pubmed">25835343</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, et al. Gut microbiome alterations in Alzheimer&#x2019;s disease. Sci Rep. 2017. October;7(1):13537. doi:10.1038/s41598-017-13601-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13601-y</ArticleId><ArticleId IdType="pmc">PMC5648830</ArticleId><ArticleId IdType="pubmed">29051531</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013. June;144(7):1394&#x2013;401, 1401.e1. doi:10.1053/j.gastro.2013.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.02.043</ArticleId><ArticleId IdType="pmc">PMC3839572</ArticleId><ArticleId IdType="pubmed">23474283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(5):1245&#x2013;1249. doi:10.1016/j.clnu.2016.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2016.08.015</ArticleId><ArticleId IdType="pubmed">27669638</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer&#x2019;s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016. November;8:256. doi:10.3389/fnagi.2016.00256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00256</ArticleId><ArticleId IdType="pmc">PMC5105117</ArticleId><ArticleId IdType="pubmed">27891089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z. Clinical and metabolic response to probiotic administration in people with Parkinson&#x2019;s disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(3):1031&#x2013;1035. doi:10.1016/j.clnu.2018.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.05.018</ArticleId><ArticleId IdType="pubmed">29891223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum GR, Olson CA, Hsiao EY. Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis. 2020. February;135:104576. doi:10.1016/j.nbd.2019.104576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104576</ArticleId><ArticleId IdType="pubmed">31445165</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Levy M, Tatirovsky E, Elinav E. Microbiome-modulated metabolites at the interface of host immunity. J Immunol. 2017. January;198(2):572&#x2013;580. doi:10.4049/jimmunol.1601247.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601247</ArticleId><ArticleId IdType="pubmed">28069752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014. May;38:1&#x2013;12. doi:10.1016/j.bbi.2013.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.12.015</ArticleId><ArticleId IdType="pmc">PMC4062078</ArticleId><ArticleId IdType="pubmed">24370461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Yi J, Zhang Y-G, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4):Apr. doi:10.14814/phy2.12356.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12356</ArticleId><ArticleId IdType="pmc">PMC4425962</ArticleId><ArticleId IdType="pubmed">25847918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-G, Wu S, Yi J, Xia Y, Jin D, Zhou J, Sun J. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017. February;39(2):322&#x2013;336. doi:10.1016/j.clinthera.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2016.12.014</ArticleId><ArticleId IdType="pmc">PMC5344195</ArticleId><ArticleId IdType="pubmed">28129947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, Chen T. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 2016. September;7:1479. doi:10.3389/fmicb.2016.01479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01479</ArticleId><ArticleId IdType="pmc">PMC5028383</ArticleId><ArticleId IdType="pubmed">27703453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, Weishaupt JH. The fecal microbiome of ALS patients. Neurobiol Aging. 2018;61:132&#x2013;137. doi:10.1016/j.neurobiolaging.2017.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.09.023</ArticleId><ArticleId IdType="pubmed">29065369</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019. July;572(7770):474&#x2013;480. doi:10.1038/s41586-019-1443-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994. June;264(5166):1772&#x2013;1775. doi:10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007. December;73(23):7767&#x2013;7770. doi:10.1128/AEM.01477-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.01477-07</ArticleId><ArticleId IdType="pmc">PMC2168041</ArticleId><ArticleId IdType="pubmed">17933936</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Guo K, Murdock BJ, Paez-Colasante X, Bassis CM, Mikhail KA, Raue KD, Evans MC, Taubman GF, McDermott AJ, et al. Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice. Dis Model Mech. 2019. November;13(2). doi:10.1242/dmm.040832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.040832</ArticleId><ArticleId IdType="pmc">PMC6906635</ArticleId><ArticleId IdType="pubmed">31597644</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. Ameliorating amyotrophic lateral sclerosis. N Engl J Med. 2010. March;362(10):953&#x2013;954. doi:10.1056/NEJMcibr0912229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr0912229</ArticleId><ArticleId IdType="pubmed">20220193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003. April;53(4):423&#x2013;426. doi:10.1002/ana.10561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10561</ArticleId><ArticleId IdType="pubmed">12666108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, D&#x2019;Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. FETR-ALS study protocol: a randomized clinical trial of fecal microbiota transplantation in amyotrophic lateral sclerosis. Front Neurol. 2019. September;10:1021. doi:10.3389/fneur.2019.01021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.01021</ArticleId><ArticleId IdType="pmc">PMC6763586</ArticleId><ArticleId IdType="pubmed">31620079</ArticleId></ArticleIdList></Reference><Reference><Citation>A study of protein metabolism, microbiome and investigational probiotic use in patients with ALS - full text view - clinicalTrials.gov. [Online]. [Accessed 21March 2020]. https://clinicaltrials.gov/ct2/show/NCT03324399.</Citation></Reference><Reference><Citation>Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol. Rep. 2017. September;5(18):e13443. doi:10.14814/phy2.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.13443</ArticleId><ArticleId IdType="pmc">PMC5617930</ArticleId><ArticleId IdType="pubmed">28947596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai C-D, Zheng -J-J, An B-C, Huang H-F, Tan Z-C. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chin Med J (Engl). 2019. August;132(15):1815&#x2013;1822. doi:10.1097/CM9.0000000000000351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000351</ArticleId><ArticleId IdType="pmc">PMC6759115</ArticleId><ArticleId IdType="pubmed">31306225</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017. April;15(1):73. doi:10.1186/s12967-017-1175-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-017-1175-y</ArticleId><ArticleId IdType="pmc">PMC5385025</ArticleId><ArticleId IdType="pubmed">28388917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom management and end-of-life care in amyotrophic lateral sclerosis. Neurol Clin. 2015. November;33(4):889&#x2013;908. doi:10.1016/j.ncl.2015.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.010</ArticleId><ArticleId IdType="pmc">PMC5031364</ArticleId><ArticleId IdType="pubmed">26515628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergendal B, McAllister A. Orofacial function and monitoring of oral care in amyotrophic lateral sclerosis. Acta Odontol Scand. 2017. April;75(3):179&#x2013;185. doi:10.1080/00016357.2016.1276212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00016357.2016.1276212</ArticleId><ArticleId IdType="pubmed">28079403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011. September;108(38):16050&#x2013;16055. doi:10.1073/pnas.1102999108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102999108</ArticleId><ArticleId IdType="pmc">PMC3179073</ArticleId><ArticleId IdType="pubmed">21876150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell. 2018. May;9(5):488&#x2013;500. doi:10.1007/s13238-018-0548-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-018-0548-1</ArticleId><ArticleId IdType="pmc">PMC5960472</ArticleId><ArticleId IdType="pubmed">29736705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002. July;59(2):280&#x2013;282. doi:10.1212/WNL.59.2.280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.2.280</ArticleId><ArticleId IdType="pubmed">12136072</ArticleId></ArticleIdList></Reference><Reference><Citation>ProGas Study Group . Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015. July;14(7):702&#x2013;709. DOI:10.1016/S1474-4422(15)00104-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00104-0</ArticleId><ArticleId IdType="pmc">PMC4578147</ArticleId><ArticleId IdType="pubmed">26027943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JH, Wu SC, Chen HJ, Kao CH, Tseng CH, Tsai CH. Risk of developing pressure sore in amyotrophic lateral sclerosis patients - a nationwide cohort study. J Eur Acad Dermatol Venereol. 2018. September;32(9):1589&#x2013;1596. doi:10.1111/jdv.14911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.14911</ArticleId><ArticleId IdType="pubmed">29512203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg C, L&#xf6;fmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010. November;156(Pt 11):3216&#x2013;3223. doi:10.1099/mic.0.040618-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mic.0.040618-0</ArticleId><ArticleId IdType="pubmed">20705661</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Eurals Consortium . Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009. December;10(5&#x2013;6):310&#x2013;323. doi:10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Pradat P-F, Salachas F, Bruneteau G, le Forestier N, Seilhean D, Hauw -J-J, Meininger V. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9(1):59&#x2013;62. doi:10.1080/17482960701656940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701656940</ArticleId><ArticleId IdType="pubmed">17924236</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018. March;17(5):423&#x2013;433. doi:10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Chung SE, Lee S, Park J, Choi S, Kim S. Experience of complementary and alternative medicine in patients with amyotrophic lateral sclerosis and their families: A qualitative study. Amyotroph Lateral Scler Frontotemporal Degener. 2016. January;17(3&#x2013;4):191&#x2013;197. doi:10.3109/21678421.2015.1125504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1125504</ArticleId><ArticleId IdType="pubmed">26735587</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams J, Lee M, Peng W. Critical review of complementary and alternative medicine use in amyotrophic lateral sclerosis: prevalence and users&#x2019; profile, decision-making, information seeking, and disclosure in the face of a lack of efficacy. Neurodegener Dis. 2018. September;18(4):225&#x2013;232. doi:10.1159/000492946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492946</ArticleId><ArticleId IdType="pubmed">30248676</ArticleId></ArticleIdList></Reference><Reference><Citation>Toepfer M, Folwaczny C, Klauser A, Riepl RL, M&#xfc;ller-Felber W, Pongratz D. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999. December;1(1):15&#x2013;19. doi:10.1080/146608299300079484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608299300079484</ArticleId><ArticleId IdType="pubmed">12365061</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019. February;18(2):211&#x2013;220. doi:10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropini C, Moss EL, Merrill BD, Ng KM, Higginbottom SK, Casavant EP, Gonzalez CG, Fremin B, Bouley DM, Elias JE, et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell. 2018. June;173(7):1742&#x2013;1754.e17. doi:10.1016/j.cell.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6061967</ArticleId><ArticleId IdType="pubmed">29906449</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, Walsh T, Kazoka M, Project MinE ALS Sequencing Consortium, Ince P. G., Hautbergue G. M., McDermott C. J., Kirby J., and Shaw P. J.. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci. 2017. November;10:370. doi:10.3389/fnmol.2017.00370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00370</ArticleId><ArticleId IdType="pmc">PMC5684183</ArticleId><ArticleId IdType="pubmed">29170628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, Mitra RD, Ravits J, Harms MB, Baloh RH. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015. January;77(1):100&#x2013;113. doi:10.1002/ana.24306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24306</ArticleId><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015. August;72(8):905&#x2013;911. doi:10.1001/jamaneurol.2015.0910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly &#xc9;J, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, Thun M, Park Y, Kolonel LN, Ascherio A. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013. April;14(3):205&#x2013;211. doi:10.3109/21678421.2012.735240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008. March;70(13):1004&#x2013;1009. doi:10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011. January;10(1):75&#x2013;82. doi:10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Clerico M, De Mercanti S, Bersano E, Cammarosano S, Ilardi A, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016. November;87(11):1229&#x2013;1233. doi:10.1136/jnnp-2016-313793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313793</ArticleId><ArticleId IdType="pubmed">27656044</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006. December;444(7122):1027&#x2013;1031. doi:10.1038/nature05414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05414</ArticleId><ArticleId IdType="pubmed">17183312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018. March;359(6380):1151&#x2013;1156. doi:10.1126/science.aao5774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao5774</ArticleId><ArticleId IdType="pubmed">29590046</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh A, Molinaro A, St&#xe5;hlman M, Khan MT, Schmidt C, Manner&#xe5;s-Holm L, Wu H, Carreras A, Jeong H, Olofsson LE, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell. 2018. November;175(4):947&#x2013;961.e17. doi:10.1016/j.cell.2018.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.09.055</ArticleId><ArticleId IdType="pubmed">30401435</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto J-M, Kennedy S, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013. August;500(7464):541&#x2013;546. DOI:10.1038/nature12506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12506</ArticleId><ArticleId IdType="pubmed">23985870</ArticleId></ArticleIdList></Reference><Reference><Citation>Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019. July;25(7):1096&#x2013;1103. doi:10.1038/s41591-019-0495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0495-2</ArticleId><ArticleId IdType="pmc">PMC6699990</ArticleId><ArticleId IdType="pubmed">31263284</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan ER, Shah A, Koloski N, Walker MM, Talley NJ, Morrison M, Holtmann GJ. Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome. 2018. August;6(1):150. doi:10.1186/s40168-018-0531-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-018-0531-3</ArticleId><ArticleId IdType="pmc">PMC6116507</ArticleId><ArticleId IdType="pubmed">30157953</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Korem T, Zilberman-Schapira G, Segal E, Elinav E. Non-caloric artificial sweeteners and the microbiome: findings and challenges. Gut Microbes. 2015. April;6(2):149&#x2013;155. doi:10.1080/19490976.2015.1017700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2015.1017700</ArticleId><ArticleId IdType="pmc">PMC4615743</ArticleId><ArticleId IdType="pubmed">25831243</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014. October;514(7521):181&#x2013;186. doi:10.1038/nature13793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13793</ArticleId><ArticleId IdType="pubmed">25231862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotkine M, Friedlander Y, Hochner H. Triathletes are over-represented in a population of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014. December;15(7&#x2013;8):534&#x2013;536. doi:10.3109/21678421.2014.932383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.932383</ArticleId><ArticleId IdType="pubmed">25007701</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, Seelen M, de Jong SW, Dorresteijn KRIS, van Doormaal PTC, van der Kooi AJ, de Visser M, Schelhaas HJ, van den Berg LH, Veldink JH. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013. September;84(9):976&#x2013;981. doi:10.1136/jnnp-2012-304724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId><ArticleId IdType="pubmed">23418211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, Zagai U, Pawitan Y, Fang F. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019. November;26(11):1355&#x2013;1361. doi:10.1111/ene.13986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13986</ArticleId><ArticleId IdType="pubmed">31087715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis SM, Gurney ME. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci. 1995. August;6(4):349&#x2013;362. doi:10.1006/mcne.1995.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.1995.1027</ArticleId><ArticleId IdType="pubmed">8846004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, Gottel N, Zhang X, Butovsky O, Gilbert JA, et al. Sex-specific effects of microbiome perturbations on cerebral A&#x3b2; amyloidosis and microglia phenotypes. J Exp Med. 2019. July;216(7):1542&#x2013;1560. doi:10.1084/jem.20182386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182386</ArticleId><ArticleId IdType="pmc">PMC6605759</ArticleId><ArticleId IdType="pubmed">31097468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, et al. Parkinson&#x2019;s disease and Parkinson&#x2019;s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017. February;32(5):739&#x2013;749. doi:10.1002/mds.26942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26942</ArticleId><ArticleId IdType="pmc">PMC5469442</ArticleId><ArticleId IdType="pubmed">28195358</ArticleId></ArticleIdList></Reference><Reference><Citation>Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA. 2017. October;114(40):10713&#x2013;10718. doi:10.1073/pnas.1711235114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1711235114</ArticleId><ArticleId IdType="pmc">PMC5635915</ArticleId><ArticleId IdType="pubmed">28893978</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA. 2017. October;114(40):10719&#x2013;10724. doi:10.1073/pnas.1711233114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1711233114</ArticleId><ArticleId IdType="pmc">PMC5635914</ArticleId><ArticleId IdType="pubmed">28893994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>